

## UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/706,299	11/11/2003	Assaf Govari	U 014946-4	5768
140 LADAS & PA	7590 04/05/200 RRY	7	EXAMINER	
26 WEST 61ST STREET NEW YORK, NY 10023		•	VRETTAKOS, PETER J	
			ART UNIT	PAPER NUMBER
			3739	
			<b>T</b>	
SHORTENED STATUTO	RY PERIOD OF RESPONSE	MAIL DATE	DELIVERY MODE	
3 MONTHS		04/05/2007	PAPER .	

Please find below and/or attached an Office communication concerning this application or proceeding.

If NO period for reply is specified above, the maximum statutory period will apply and will expire 6 MONTHS from the mailing date of this communication.

	Application No.	Applicant(s)				
Office Astion Comments	10/706,299	GOVARI ET AL.				
Office Action Summary	Examiner	Art Unit				
	Peter J. Vrettakos	3739				
The MAILING DATE of this communication ap Period for Reply	pears on the cover sheet wi	th the correspondence addres	s			
A SHORTENED STATUTORY PERIOD FOR REPL WHICHEVER IS LONGER, FROM THE MAILING D  - Extensions of time may be available under the provisions of 37 CFR 1. after SIX (6) MONTHS from the mailing date of this communication.  - If NO period for reply is specified above, the maximum statutory period  - Failure to reply within the set or extended period for reply will, by statute Any reply received by the Office later than three months after the mailin earned patent term adjustment. See 37 CFR 1.704(b).	OATE OF THIS COMMUNION (136(a). In no event, however, may a rewill apply and will expire SIX (6) MON e, cause the application to become AB	CATION.  eply be timely filed  THS from the mailing date of this communication  ANDONED (35 U.S.C. § 133).				
Status						
1)⊠ Responsive to communication(s) filed on <u>08 </u>	March 2007					
	s action is non-final.					
· <u> </u>	,—					
closed in accordance with the practice under	•	• •				
Disposition of Claims		,				
. 4)⊠ Claim(s) <u>18-25 and 28-30</u> is/are pending in the	e annlication					
4a) Of the above claim(s) is/are withdra	• •					
5) Claim(s) is/are allowed.						
6)⊠ Claim(s) <u>18-25 and 28-30</u> is/are rejected.						
7) ☐ Claim(s) is/are objected to.	•					
8) Claim(s) are subject to restriction and/o	or election requirement					
Application Papers	or erection requirement.					
9) The specification is objected to by the Examine		hoo Alba Forensinaa				
10) The drawing(s) filed on is/are: a) acc	·					
Applicant may not request that any objection to the	• • • • • • • • • • • • • • • • • • • •	` , ,	4047.0			
Replacement drawing sheet(s) including the correct 11) The oath or declaration is objected to by the Ex	•	, ,	` '			
Priority under 35 U.S.C. § 119	xammer. Note the attached	TOTILE ACTION OF IOTH F 10-15	JZ.			
<u>.                                     </u>						
<ul> <li>12) Acknowledgment is made of a claim for foreign</li> <li>a) All b) Some * c) None of:</li> <li>1. Certified copies of the priority document</li> </ul>		119(a)-(d) or (f).				
2. Certified copies of the priority document	2. Certified copies of the priority documents have been received in Application No					
<ol> <li>Copies of the certified copies of the prio application from the International Burea</li> </ol>	rity documents have been u (PCT Rule 17.2(a)).	received in this National Stag	e			
* See the attached detailed Office action for a list of the certified copies not received.						
Attachment(s)						
Notice of References Cited (PTO-892)		ummary (PTO-413)				
2)  Notice of Draftsperson's Patent Drawing Review (PTO-948) 3)  Information Disclosure Statement(s) (PTO/SB/08)		)/Mail Date Iformal Patent Application				
Paper No(s)/Mail Date	6) Other:					

## **DETAILED ACTION**

The application is published application number: 2005/0101946.

The effective filing date of this application is 11-11-03.

The action is non-final. An RCE was filed 3-8-07.

Claims 18-25 and 28-30 are pending

## Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

Claims 18-25 and 28-30 are rejected under 35 U.S.C. 103(a) as being unpatentable over Walsh (6,802,857) in view of Spillman, Jr. et al. (6,206,835).

Walsh is silent regarding a control circuit and physiological sensors.

<u>Independent claim 18 (and 30) (parentheticals toward Walsh unless stated otherwise)</u>

Walsh discloses a system for electrically isolating a cardiac chamber, comprising: a resonant circuit (18, col. 4:14) having a resonant frequency, said resonant circuit being constructed and dimensional for introduction into an operative position in a pulmonary vein (anticipated by language toward a "vessel" in col.

4:1-3; also note that this is intended use language) of a subject proximate an ostium of said pulmonary vein (intended use language);

a catheter (col. 1:44-48) adapted to carry said resonant circuit into said operative position in said pulmonary vein;

a stent (10) dimensioned for circumferential engagement with an inner wall of said pulmonary vein (intended use language; analogues disclosed: artery, passageway, see col. 4:1-3) to define a circumferential region (depicted in figure 8, element 46 is the vessel, the RF field is 36) of contact between said stent (10) and said pulmonary vein (intended use language), wherein a principal axis of said stent is substantially aligned coaxially (depicted in figure 8, element 46 is the vessel, the RF field is 36) with said pulmonary vein, said resonant circuit being incorporated in said stent (incorporation disclosed at least once, see col. 4:22-24); and

a generator (col. 5:65 through col. 6:6; col. 1:8-10) disposed external to said subject for generating an electromagnetic field that has a frequency substantially equal to said resonant frequency of said resonant circuit, said electromagnetic field operatively including said resonant circuit and causing said resonant circuit to re-radiate electromagnetic energy so as to ablate (col. 5:50-65) intramural target tissue in said pulmonary vein; and

a sensor system (68 Spillman patent) to position and orient (as determined by

changes in blood pressure once the stent is in place as opposed to being mobile;

also note that **Spillman** discloses that the sensor can detect other parameters,

col. 7:47-48) said stent in said pulmonary vein (analogues passageways and

arteries disclosed in Walsh col. 4:1-4) proximate the ostium (intended use).

Note: a recitation of the intended use of the claimed invention must result in a structural

difference between the claimed invention and the prior art in order to patentably

distinguish the claimed invention from the prior art. If the prior art structure is capable

of performing the intended use, then it meets the claim. (Also note that analogues to a

pulmonary vein are disclosed: arteries and passageways in col. 4:1-3. This increases

the likelihood that the Walsh structure is capable of use in the pulmonary vein as the

Applicant claims.)

Dependent claims

22. The system according to claim 18, wherein said stent is constructed of an alloy

having a shape memory (col. 4:4-6, "nitinol").

23. The system according to claim 18, wherein said stent is constructed of a

biodegradable material (col. 4:4-6, "nitinol").

However, in an analogous device/method (see the stent 32 in figure 6a), **Spillman** discloses a sensor (68) for monitoring electrophysiologic cardiac properties (blood pressure, col. 7:32) of said subject for determining if a predefined end point has been reached.

- 20. The combination of the two patents suggest predefined end point comprises confirmation of a block of electrical conductivity at said target tissue (intended use language). Also note that an abrupt change in sensed blood pressure (blood pressure, col. 7:32; sensed parameters related to impedance, resistance, capacitance col. 7:26-34 and col. 7:45-55) in theory could **capably** provide confirmation of a conduction block.
- 21. The combination of the two patents suggest a plurality of capacitors (C1, C2 in figure 5a in Walsh) in said resonant circuit; and a **control circuit** (60 in Spillman figure 3) for automatically selecting one of said capacitors responsively to a frequency of said electromagnetic field to so as to conform said resonant frequency of said resonant circuit with said frequency of said electromagnetic field.
- 24. The system according to claim 18, further comprising: a localizing subsystem (60 Spillman) for tracking a position and orientation of said catheter (through sensing with 68, Spillman), comprising: a plurality of localizing field generators (65) disposed external to said subject; a position (68) sensor on said catheter that is responsive to localizing

electromagnetic fields produced by said localizing field generators; and a receiver (65) responsive to an output of said position sensor.

The <u>motivation</u> to combine the patents is to monitor the condition of the implant/stent as allowed by the Spillman stent depicted in figure 6a and is found in Spillman col. 1:22-24.

Therefore, at the time of the invention in would have been obvious to one of ordinary skill in the art to modify Walsh in view of Spillman by including feedback and position sensors. Again, the <u>motivation</u> to combine the patents is to monitor the condition of the implant/stent and is found in Spillman col. 1:22-24.

- 25. The system according to claim 18 wherein said stent (10) and said resonant circuit (18) form a body in the shape of a ring oriented in a plane extending radially of the axis of the pulmonary vein (intended use). This is depicted in Walsh figure 8. (46 is a vessel, which includes by definition the pulmonary vein.)
- 28. The system according to claim 25 wherein said stent is positioned in facing relative to the ostium of the pulmonary vein. *This is intended use language*.
- 29. The system according to claim 28 wherein the position of the stent relative to said

ostium is such that the target tissue is ablated near said ostium to block electrical conductivity of said tissue and thereby counteract arrhythmia in the heart chamber. *This is intended use language*.

## Response to Arguments

Applicant's arguments filed 3-8-07 have been fully considered but they are not persuasive.

Walsh discloses a stent 12 with conducting wire 20 forming an inductor 14. The stent has two capacitors 16 bookmarking the inductor 20. As such the wire 20 is **between** the capacitors 16. Amended claim 18 and new claim 30 currently disclose a stent having a capacitor core and an inductor coil wound **around** a capacitor. In response, the Office applies the following case law evincing obvious the differences between the Walsh and the claimed invention.

In re Japikse, 181 F.2d 1019, 86 USPQ 70 (CCPA 1950) (Claims to a hydraulic power press which read on the prior art except with regard to the position of the starting switch were held unpatentable because shifting the position of the starting switch would not have modified the operation of the device.); In re Kuhle, 526 F.2d 553, 188 USPQ 7 (CCPA 1975) (the particular placement of a contact in a conductivity measuring device was held to be an obvious matter of design choice).

In light of the above case law, the Office contends it obvious (as a design choice) to place the Walsh wire <u>around</u> a capacitor which would read on the Applicant's claimed invention. Further, the rearrangement of parts (<u>between to around</u>) would not have modified the the operation of the Walsh stent.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Peter J. Vrettakos whose telephone number is 571-272-4775. The examiner can normally be reached on M-F 9-6.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Linda C. Dvorak can be reached on 571-272-4764. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Application/Control Number: 10/706,299 Page 8

Art Unit: 3739

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Pete Vrettakos March 30, 2007

ROY D. GIBSON PRIMARY EXAMINER